






LPAC et Hépatolithiase

Paris, 10 Mai 2012






MDR3 : Historique


- **1988 : clonage et séquençage du gène**
- **1993 : premier modèle de souris ko (absence de phospholipides dans la bile + inflammation biliaire)**
- **1996 : absence d'expression hépatique de la protéine au cours de PFIC3**
- **2001 : les mutations hétérozygotes du gène sont associées au syndrome LPAC et à la cholestase gravidique**
- **2004 : la souris mdr2 $-/-$ développe une cholangite sclérosante et une lithiase biliaire intrahépatique**







Case	Age	Sex	Age at diagnosis (yr)	Features at presentation	Familial history	Follow-up
	35	F	28	Cholestasis and biliary pain during pregnancy with stillborn fetus Cholecystectomy Recurrence after cholecystectomy	Parents (1a and 1b) free of symptom	Free of symptom and norm liver enzymes under UDC during a 2nd pregnancy
	41	F	25	Cholestasis and biliary pain during pregnancy; premature baby Cholecystectomy Recurrence after cholecystectomy	Husband (2a) free of symptom, son (case 3) cholesterol cholelithiasis	Cholestasis during the 2nd pregnancy Free of symptom and norm liver enzymes under UDC
	26	M	24	Cholestasis and biliary pain Cholecystectomy Recurrence after cholecystectomy	Brother (17 years old) (3a) free of symptom	Free of symptom and norm liver enzymes under UDC
	34	F	22	Cholestasis and biliary pain after starting oral contraception and during pregnancy; premature baby Cholecystectomy Recurrence after cholecystectomy	Father gallbladder gallstones at the age of 30	Cholestasis after starting progesterone treatment view to in vitro fertilization Free of symptom and norm liver enzymes under UDC
	55	F	15	Cholestasis and biliary pain Cholecystectomy Recurrence after cholecystectomy	Mother gallbladder gallstones at the age of 27, son and daughter (29 years old) free of symptom (5a 5b)	Cholestasis and biliary pain Free of symptom and norm liver enzymes under UDC
	60	M	55	Cholestasis and biliary pain Cholecystectomy Recurrence after cholecystectomy	Two daughters (28 and 33 years old) without experience of pregnancy and free of symptom	Free of symptom and norm liver enzymes under UDC
















Nature et localisations des mutations identifiées



Description du syndrome LPAC (*Low Phospholipid Associated Cholelithiasis*)

- Symptômes biliaires **avant 40 ans**.
- Au moins un épisode de **colique hépatique** ou d'angiocholite ou de pancréatite aiguë.
- **Cholestase** chronique modérée.
- **Récidive** des symptômes après cholécystectomie.
- Matériel **échogène** dans les voies biliaires intrahépatiques.
- Apparition des symptômes au décours d'une **grossesse**.
- Efficacité de l'**AUDC** sur les symptômes et leur récurrence.



60 patients with symptomatic cholelithiasis




MDR3 gene analysis


18 patients with MDR3 gene mutations

42 patients without MDR3 gene mutations

Odds Ratios for the presence of ABCB4 gene mutations in patient with LPAC

Clinical criterion	OR	p
Familial history of cholelithiasis	5,4	0,01
Increased serum GGT activity	1,1	1
History of ICP	4,9	0,02
Intrahepatic hyperechoic material	12,4	0,0005
Recurrence after cholecystectomy	18,9	< 0,0001
Age < 40 at the onset of symptoms	7,8	0,008
Gender (M vs F)	0,8	1






Caractéristiques cliniques des 156 patients avec le syndrome LPAC

	avec mutation n = 79	sans mutation n = 77	
Type de mutation	Non sens 25 % Faux sens 75 %	—	
Age de survenue des symptômes (ans)	32 ± 12	32 ± 11	(ns)
Sex ratio (% femmes)	70 %	63 %	(ns)
Complications biliaires :	57 %	64 %	
- aiguës	39 %	51 %	(ns)
- chroniques	18 %	13 %	
Grossesses (n)	44	19	
- Cholestase gravidique	52 %	42 %	(ns)
- Complication foetal	14 %	21 %	


Localisation des mutations du gène ABCB4



Localisation des mutations du gène ABCB4

Hétérozygotes	73	Mutation non sens	25,0 %
Hétérozygotes composites	2	N terminal	3,5 %
Homozygotes	4	1 ^{ère} boucle IC	8,3 %
– Faux sens	4	2 ^{ème} boucle IC	1,2 %
– Non sens	0	3^{ème} boucle IC	28,0 %
		4 ^{ème} boucle IC	3,5 %
		5 ^{ème} boucle IC	4,8 %
		TM 1, 2, 5, 7, 8	15,5 %
		1 ^{ère} boucle EC	3,5 %
		4 ^{ème} boucle EC	1,2 %
		6 ^{ème} boucle EC	1,2 %




Age de survenue des douleurs biliaires en fonction du type de mutation et du sexe




Age moyen aux symptômes

Homme et mutation faux sens	40 ± 13 ans	
Homme et mutation non sens	30 ± 13 ans	P = 0,001
Femme et mutation faux sens	31 ± 12 ans	
Femme et mutation non sens	26 ± 6 ans	


Complications biliaires en fonction du sexe, du type de mutation et de l'âge de survenue des symptômes




Survenue d'une cholestase gravidique en fonction du type de mutation







Dilatation non kystique des voies biliaires au cours du syndrome LPAC




Dilatation non kystique segmentaire au cours du syndrome LPAC








- Attenuated form of LPAC syndrome
- Bile duct dilatation with cholesterol gallstones and LPAC syndrome












**Overlapping features of Progressive Familial
Intrahepatic Cholestasis 3 and Low Phospholipid-
Associated Cholelithiasis in two adult siblings with
ABCB4 heterozygous compound status.**

Patrick Chamouard, Véronique Barbu, Dominique Wendum,
Chantal Housset, Olivier Rosmorduc, Raoul Poupon

Extracellular



PFIC3 Mutations

AA	Ref.	Var.	AA	Ref.	Var.	AA	Ref.	Var.
27	S	fs+X	424	T	A	715	T	I
96	V	fs+X	425	V	M	723	G	E
126	G	E	475	V	A	724	L	fs+X
132	Y	fs+X	511	A	T	726	P	T
138	W	R	541	I	F	737	A	V
159	R	X	556	L	R	762	G	X
250	A	P	558	E	K	775	T	M
279	Y	X	564	D	G	840	A	D
286	A	V	571	V	fs+X	888	E	X
346	S	I	593	M	A	953	A	D
357	F	L	630	T	V	954	G	S
364	A	V	636	Q	X	957	R	X
379	S	fs+X	701	L	P	981	V	fs+X
395	E	G	711	F	S	983	G	S
403	Y	H						


LPAC Mutations

AA	Ref.	Var.
165	F	I
175	T	A
180	D	fs+X
301	M	T
320	S	F
336	V	fs+X
443	Q	fs+X
528	E	D
545	R	G
559	A	T
591	L	Q
658	W	X
756	L	fs+X
788	R	E
934	A	T
1161	P	S

Cytoplasm

Nor-ursodeoxycholic acid (norUDCA)

- Side chain-shortened homologue of UDCA



INSERM UMR 1153 UNIVERSITÉ DE BORDEAUX U1013 UNIVERSITÉ DE LAUSANNE UNIVERSITÉ DE STRASBOURG Inserm
©AP-HP, UPMC, INSERM - RYJC 2007

- More hydrophilic and conjugation resistant
- Cholehepatic shunting, HCO₃-rich choleresis
- Reverses sclerosing cholangitis in mdr2^{-/-} mice

Syndrômes cholestatiques associés aux mutations du gène MDR3

- **Associations certaines**
 - **PFIC3**
 - **Cholestase, ductopénie, fibrose et cirrhose biliaires de l'adulte**
 - **Cholestase gravidique (à GGT élevées)**
 - **Syndrôme LPAC (sans ou avec dilatation segmentaire des voies biliaires intrahépatiques)**
- **Associations probables ou possibles**
 - **Hépatolithiase orientale**
 - **Cholestase médicamenteuse**
 - **Cholestase de la nutrition parentérale**
 - **Cholestase et cholangiopathie du sepsis**
 - **Cholangiopathie post-transplantation**
 - **CBP, CSP**

